Changes in Energy Expenditure (EE) in Transsexuals Undergoing Hormonal Therapy
Launched by TEL-AVIV SOURASKY MEDICAL CENTER · Dec 10, 2024
Trial Information
Current as of July 04, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Study Objective
1. To assess energy expenditure including: resting energy expenditure (RER), - in transgender subjects undergoing hormonal gender affirming treatment.
2. To assess change in Physical Activity (PA) before and after treatment. Methods Study design: A pilot observational prospective study, recruiting 20 transsexuals: 10 transwomen (TW) and 10 transmen (TM).
Criteria for inclusion
1. TW and TM with no prior hormonal therapy in the last one year.
2. Stable weight in last six months (\<±5% weight change),
Criteria for exclusion
1. Postmenopausal TM.
2. Oral contraceptive use....
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. TW and TM with no prior hormonal therapy in the last one year. 2. Stable weight in last six months (\<±5% weight change),
- • -
- Exclusion Criteria:
- • 1. Postmenopausal TM.
- • 2. Oral contraceptive use.
- • 3. Pregnancy or breastfeeding.
- • 4. Glucocorticosteroid treatment
- • 5. Uncontrolled thyroid disorders
- • 6. Use of drugs that potentially impact body metabolism
About Tel Aviv Sourasky Medical Center
Tel Aviv Sourasky Medical Center, a leading academic medical institution in Israel, is renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a multidisciplinary approach, the center integrates cutting-edge medical technology and evidence-based practices to enhance patient care and outcomes. Its robust infrastructure supports a diverse range of clinical studies, fostering collaboration among healthcare professionals, researchers, and industry partners. The center's dedication to research excellence and patient safety positions it as a key player in the global clinical research landscape, driving advancements in medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv Yafo, , Israel
Patients applied
Trial Officials
Yael Sofer, MD
Principal Investigator
Department of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center and Tel Aviv University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported